Jasper Therapeutics, Inc. (NASDAQ:JSPR) Sees Significant Increase in Short Interest

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the target of a large growth in short interest in July. As of July 31st, there was short interest totaling 4,311,877 shares, a growth of 159.5% from the July 15th total of 1,661,803 shares. Approximately 15.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 4,576,589 shares, the short-interest ratio is presently 0.9 days.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR opened at $0.86 on Friday. The company has a market cap of $24.17 million, a P/E ratio of -0.27 and a beta of 3.02. Jasper Therapeutics has a 52-week low of $0.32 and a 52-week high of $3.14. The firm’s fifty day moving average is $0.59 and its two-hundred day moving average is $0.91.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.08. As a group, analysts forecast that Jasper Therapeutics will post -1.67 EPS for the current fiscal year.

Institutional Trading of Jasper Therapeutics

Several hedge funds have recently made changes to their positions in the business. Velan Capital Investment Management LP increased its stake in Jasper Therapeutics by 86.1% during the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after acquiring an additional 1,234,567 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Jasper Therapeutics by 6,394.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock worth $3,196,000 after acquiring an additional 1,719,602 shares during the period. Acorn Capital Advisors LLC bought a new stake in Jasper Therapeutics during the 3rd quarter valued at $3,291,000. Millennium Management LLC raised its holdings in shares of Jasper Therapeutics by 194.2% in the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock valued at $1,965,000 after acquiring an additional 708,844 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in shares of Jasper Therapeutics in the 3rd quarter valued at about $2,475,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. TD Cowen downgraded Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Piper Sandler initiated coverage on Jasper Therapeutics in a research report on Wednesday. They set an “overweight” rating and a $2.00 target price for the company. Wall Street Zen raised Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Royal Bank Of Canada set a $3.00 price target on Jasper Therapeutics and gave the stock a “sector perform” rating in a research note on Friday, May 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Jasper Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $10.57.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.